Understanding how a specific microRNA influences retinal cell development
Control of retinal cell fate specification by the miR9-2 disease gene locus
This study is looking at how a tiny molecule called miR9-2 helps control the development of different types of cells in the eye, which could help us understand eye diseases better and find new ways to treat them.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Seattle Children's Hospital NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-10995184 on NIH RePORTER |
What this research studies
This research investigates the role of the microRNA miR9-2 in the development of retinal cells, focusing on how it regulates the timing of cell fate specification in the retina. By utilizing in vivo mouse models and advanced techniques like single-cell sequencing, the researchers aim to uncover the mechanisms by which miR9-2 and its enhancer influence the emergence of different retinal cell types. This study is crucial for understanding the genetic factors that contribute to retinal diseases, potentially leading to new therapeutic strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk for or diagnosed with retinal diseases, particularly age-related macular degeneration.
Not a fit: Patients with retinal conditions unrelated to the mechanisms being studied, or those who do not have a genetic predisposition to these diseases, may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new insights and treatments for retinal diseases, including age-related macular degeneration.
How similar studies have performed: Other research has shown promising results in understanding the role of non-coding elements in cell fate specification, indicating that this approach has potential for success.
Where this research is happening
Seattle, United States
- Seattle Children's Hospital — Seattle, United States (Active)
Researchers
- Principal investigator: Callies, Katelyn Ning Lulu — Seattle Children's Hospital
- Study coordinator: Callies, Katelyn Ning Lulu
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.